Price quotes for Sibutramine from multiple providers

Wed Jun 25, 3:23 AM ET

…

The July-August 2005 issue of the Journal of
Managed Care Pharmacy (JMCP) is now available in print and online.
Featured articles include:

Cost-Effectiveness of Sibutramine (Meridia) Within a Managed Care
Weight-Loss Program …

Pharmacoeconomic evaluation of the results from a prospective randomized
trial found that adding sibutramine to a comprehensive weight management
behavioral modifica…

To the Editor:

Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
Ho…

Medication compliance is notoriously poor in all conditions. The long-term management of obesity is particularly beset by medication noncompliance. The risk for weight regain is even greater than the risk for those with major organ cancer to succumb to the cancer. Long-term medication use could become an increasingly necessary proposition. Understanding medication compliance in the treatment of o…

Apfelboum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106:179-84.
Clinical question Does sibutram…

Orlistat, a gastrointestinal lipase inhibitor, and sibutramine, a serotonin-noradrenaline reuptake inhibitor, were licensed in UK for the treatment of obesity in December 1998 and May 2001, respectively. In clinical trials, orlistat was associated mainly with mild to moderate gastrointestinal adverse events, such as diarrhea, flatus, and oily or fatty stools, whereas the most commonly re…

With the rise of obesity, there is an increasing need for effective treatment of this chronic disorder. Recently, several drugs have been discovered that are designed to be used as an adjunct to nonmedical therapy in the treatment of obesity. The main objective of this pharmacotherapeutic approach is to achieve long-term weight loss and there is evidence that even moderate weight loss of 5-10 percent results in reduc…

TO THE EDITOR:
While Dr Sheperd’s review of obesity management (”Effective management of obesity,” 2003; 52(1):34-42) is timely and appropriate, given the significant impact of this problem for both the individual and society, unfortunately his brief review of sibutramine therapy contains an inaccuracy. Although he correctly states that sibutromlne is approved by …

Obesity has reached endemic proportions and the widespread lack of clinical success calls for effective treatment of this chronic disorder. The reluctance of the medical community to treat obesity is fortunately no longer justified because short-term weight reduction achieved by interventions such as dieting, exercise, and behavior modification programs, can lead to long-term weight loss through the use of effective medicines. These drugs are designed to …

TO THE EDITOR:
In their commentary on the article by Wirth and Krause, (1) Drs Stevenson, Trojian, and Jackson (2) questioned the use of sibutramine in races other than whites and the use of the drug beyond 1 year because long-term health and mortality benefits have not been established.
Regarding the forme…